Insight

Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer

Photo from Cancer Research Communications/X

May 22, 2024, 01:03

Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer

Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Centre, shared a post by Cancer Research Communications on X, adding:

“Pleased to announce the first trial to demonstrate benefit of systemic therapy in appendiceal cancer. Atezolizumab and Bevacizumab; significantly improved PFS compared to synthetic cohort.

Median PFS 18.3 vs 4.4 months. Thanks to John Paul Shen and Kanwal Raghav for mentorship.” .

Quoting Cancer Research Communications’ post:

“Just published: Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma, by Nicholas Hornstein et al.”

Source: Nicholas Hornstein/X and Cancer Research Communications/X

appendiceal adenocarcinoma appendiceal cancer atezolizumab Bevacizumab cancer Cancer Research Communications John Paul Shen Kanwal Raghav MD Anderson Cancer Centre Nicholas Hornstein OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage